



COPY OF PAPERS
ORIGINALLY FILED

#3

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO: ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON THE DATE INDICATED BELOW.

BY: L. McFours

DATE: 2-22-02

**PATENT
BOX SEQUENCE**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent Application of EVA REDEI	: Group Art Unit: 1631 : : :
Appln. No.:	10/004,970	: Examiner: Not Yet Assigned : :
Filed:	December 3, 2001	: : :
For:	ANTI-DEPRESSANT EFFECTS OF CORTICOTROPIN RELEASE INHIBITING FACTOR	: Attorney Docket : No. 048626-5003-01 : (NU 99011)

PRELIMINARY AMENDMENT

Preliminary to examining the above-referenced application, please amend the application as follows:

In the Specification:

Please amend the specification to include the substitute paper copy of the Sequence Listing and corresponding diskette, included herewith.

REMARKS

Applicant has substituted the paper copy of the Sequence Listing and the corresponding diskette submitted herewith in order to comply with the Notice to Comply with Requirements for Patent Applications Containing Nucleotide and/or Amino Acid Sequence Disclosures. Applicant submits that no new matter has been added by way of this Amendment.

Applicant notes that the paper copy of the Sequence Listing was filed with the application on December 3, 2001, as was a request to transfer the diskette from the parent application to the present application. Apparently, this request was not granted. The paper copy of the Sequence Listing submitted herewith is identical to the paper copy submitted with the application, except that the Sequence Listing now includes the application data information for the present application. The diskette is identical to the paper copy of the Sequence Listing.

Applicant respectfully requests that the Examiner contact the undersigned representative as soon as possible should this Amendment and the substitute paper and computer copies of the Sequence Listing not satisfy the Notice to Comply.

Respectfully submitted,

EVA REDEI

February 22, 2002
Date

By:

Kathryn Doyle
KATHRYN DOYLE, Ph.D, J.D.
Registration No. 36,317
MORGAN, LEWIS & BOCKIUS, LLP
1701 Market Street
Philadelphia, PA 19103-2921
Telephone: (215) 963-5000
Direct Dial: (215) 963-4723
Facsimile: (215) 963-5299
E-Mail: kdoyle@morganlewis.com
Attorney for Applicants

KD/GHL

Enclosures: Sequence Listing in Paper and Computer Readable Format
Statement to Support Sequence Listing

COPY OF PAPERS
ORIGINALLY FILED

UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

MAR 06 2002

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/004,970	12/03/2001	Eva Redei	048626-5003-01

CONFIRMATION NO. 8481

028977
MORGAN, LEWIS & BOCKIUS LLP
1701 MARKET STREET
PHILADELPHIA, PA 19103-2921

FORMALITIES LETTER



OC000000007390920

Date Mailed: 01/30/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE